• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺乳头状癌淋巴结转移中生长模式和侵袭性的优势以及 BRAF 和 RAS 突变的有限影响。

The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.

机构信息

Pathology Department, Hospital de São João, Oporto, Portugal.

出版信息

Virchows Arch. 2011 Sep;459(3):265-76. doi: 10.1007/s00428-011-1133-7. Epub 2011 Jul 28.

DOI:10.1007/s00428-011-1133-7
PMID:21796448
Abstract

Prognostic factors indicative of papillary thyroid carcinoma (PTC) aggressive behaviour remain incompletely established partially due to the different composition of the series on record regarding the relative proportion of classic PTC (CPTC) and follicular variant PTC (FVPTC) subtypes. Several clinico-morphological features of PTC, together with the occurrence of BRAF mutations, are still not fully accepted as markers of aggressiveness. In the present clinico-pathological study of a series of 75 CPTC and FVPTC cases, we evaluated the relative contribution of the morphological features of the tumours and their BRAF and N-RAS status for the occurrence of nodal metastases. The morphological features most closely related to the occurrence of nodal metastases were extra-thyroid extension and poorly circumscribed growth pattern, in both CPTC and FVPTC. Additional features significantly associated to nodal metastases were multicentricity in the CPTC and vascular invasion in the FVPTC group. BRAF V600E mutation was detected in 29% of tumours, 41% of CPTC and 16% of FVPTC; N-RAS Q61R mutation was detected in 6% of tumours, 3% of CPTC and 10% of FVPTC. BRAF mutation was significantly more frequent in the CPTC group and in females, and it was detected only in patients older than 20 years, suggesting a late tumourigenic effect in the development of PTC. BRAF mutation was not significantly associated to any of the other studied features related to aggressiveness or nodal metastases. These results highlight the importance of infiltrative growth pattern and invasiveness over the presence of BRAF mutation in classic and follicular variant PTC for the development of nodal metastases.

摘要

提示甲状腺乳头状癌(PTC)侵袭性行为的预后因素尚未完全确定,部分原因是记录的系列中经典 PTC(CPTC)和滤泡变异型 PTC(FVPTC)亚型的相对比例不同。PTC 的一些临床形态特征,以及 BRAF 突变的发生,尚未完全被认为是侵袭性的标志物。在本项关于 75 例 CPTC 和 FVPTC 病例的临床病理研究中,我们评估了肿瘤的形态特征及其 BRAF 和 N-RAS 状态对发生淋巴结转移的相对贡献。与发生淋巴结转移最密切相关的形态特征是甲状腺外延伸和边界不规则生长模式,在 CPTC 和 FVPTC 中均如此。与淋巴结转移显著相关的其他特征是 CPTC 的多中心性和 FVPTC 组的血管侵犯。在 29%的肿瘤中检测到 BRAF V600E 突变,在 41%的 CPTC 和 16%的 FVPTC 中检测到;在 6%的肿瘤中检测到 N-RAS Q61R 突变,在 3%的 CPTC 和 10%的 FVPTC 中检测到。BRAF 突变在 CPTC 组和女性中更为频繁,仅在 20 岁以上的患者中检测到,这表明在 PTC 的发生中存在晚期肿瘤发生效应。BRAF 突变与任何其他研究的侵袭性或淋巴结转移相关特征均无显著相关性。这些结果强调了浸润性生长模式和侵袭性在经典和滤泡变异型 PTC 发生淋巴结转移中的重要性,而不是 BRAF 突变的存在。

相似文献

1
The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.甲状腺乳头状癌淋巴结转移中生长模式和侵袭性的优势以及 BRAF 和 RAS 突变的有限影响。
Virchows Arch. 2011 Sep;459(3):265-76. doi: 10.1007/s00428-011-1133-7. Epub 2011 Jul 28.
2
Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma.肿瘤内淋巴管密度与淋巴结转移的存在相关,并将包膜型和浸润型甲状腺乳头状癌区分开来。
Virchows Arch. 2011 Dec;459(6):595-605. doi: 10.1007/s00428-011-1161-3. Epub 2011 Nov 12.
3
Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.甲状腺乳头状癌滤泡型(FVPTC):组织学特征、BRAF V600E突变及淋巴结状态
J Cancer Res Clin Oncol. 2015 Oct;141(10):1749-56. doi: 10.1007/s00432-015-1939-9. Epub 2015 Feb 22.
4
Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities.甲状腺乳头状癌的滤泡状变体:包膜型、非包膜型和弥漫型:不同的生物学和临床实体。
Arch Otolaryngol Head Neck Surg. 2012 Mar;138(3):227-33. doi: 10.1001/archoto.2011.1466.
5
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.甲状腺乳头状癌晚期伴发RAS、RET/PTC或BRAF基因突变。
Thyroid. 2014 Aug;24(8):1256-66. doi: 10.1089/thy.2013.0610. Epub 2014 Jun 10.
6
Risk factors for central neck lymph node metastases in follicular variant vs. classic papillary thyroid carcinoma.滤泡型与经典型甲状腺乳头状癌中央颈部淋巴结转移的危险因素。
Endocrine. 2018 Oct;62(1):64-70. doi: 10.1007/s12020-018-1607-3. Epub 2018 May 16.
7
Comprehensive Transcriptomic and Genomic Profiling of Subtypes of Follicular Variant of Papillary Thyroid Carcinoma.滤泡型甲状腺癌亚型的全面转录组和基因组分析。
Thyroid. 2018 Nov;28(11):1468-1478. doi: 10.1089/thy.2018.0198. Epub 2018 Oct 16.
8
Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.滤泡型甲状腺乳头状癌的分子基因分型与细针穿刺细胞学诊断类别相关:RAS 基因突变检测的价值。
Thyroid. 2013 Nov;23(11):1416-22. doi: 10.1089/thy.2012.0640. Epub 2013 Jul 25.
9
[Mutation of RAS gene in follicular-differentiated thyroid tumors and its significance].[滤泡分化型甲状腺肿瘤中RAS基因的突变及其意义]
Zhonghua Bing Li Xue Za Zhi. 2020 Mar 8;49(3):256-261. doi: 10.3760/cma.j.issn.0529-5807.2020.03.007.
10
Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern).甲状腺微小乳头状癌:106例临床病理研究,重点关注其形态学亚型(组织学生长模式)
Thyroid. 2009 Feb;19(2):119-27. doi: 10.1089/thy.2008.0303.

引用本文的文献

1
A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma.一种评估BRAF和RAS突变对甲状腺乳头状癌患者预后影响的计算方法。
Endocrine. 2024 Nov;86(2):707-722. doi: 10.1007/s12020-024-03911-3. Epub 2024 Jun 17.
2
Redox Homeostasis in Thyroid Cancer: Implications in Na/I Symporter (NIS) Regulation.甲状腺癌中的氧化还原平衡:对钠/碘同向转运体(NIS)调节的影响。
Int J Mol Sci. 2022 May 30;23(11):6129. doi: 10.3390/ijms23116129.
3
BRAF V600E and lymph node metastases in papillary thyroid cancer.

本文引用的文献

1
Follicular thyroid carcinoma.滤泡状甲状腺癌。
Mod Pathol. 2011 Apr;24 Suppl 2:S10-8. doi: 10.1038/modpathol.2010.133.
2
Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.BRAF 诱导的甲状腺癌的进展与上皮-间充质转化有关,需要同时激活 MAP 激酶和 TGFβ 信号通路。
Oncogene. 2011 Jul 14;30(28):3153-62. doi: 10.1038/onc.2011.44. Epub 2011 Mar 7.
3
Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status.
BRAF V600E与甲状腺乳头状癌中的淋巴结转移
Endocr Connect. 2020 Oct;9(10):999-1008. doi: 10.1530/EC-20-0420.
4
Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus.整合素β4促进甲状腺乳头状癌的侵袭和失巢凋亡抗性,且在淋巴管瘤栓中持续过表达。
J Cancer. 2019 Oct 21;10(26):6635-6648. doi: 10.7150/jca.36125. eCollection 2019.
5
Molecular mutations as a possible factor for determining extent of thyroid surgery.分子突变作为决定甲状腺手术范围的一个可能因素。
J Otolaryngol Head Neck Surg. 2019 Oct 17;48(1):51. doi: 10.1186/s40463-019-0372-5.
6
Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.广泛淋巴结转移的甲状腺微小乳头状癌的突变特征。
Endocrine. 2019 Apr;64(1):130-138. doi: 10.1007/s12020-019-01842-y. Epub 2019 Jan 15.
7
Predictive Value of BRAF Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.BRAF 突变对甲状腺乳头状癌淋巴结转移的预测价值:Meta 分析。
Curr Med Sci. 2018 Oct;38(5):785-797. doi: 10.1007/s11596-018-1945-7. Epub 2018 Oct 20.
8
MicroRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF.微小RNA-9-5p通过靶向BRAF在甲状腺乳头状癌中发挥肿瘤抑制作用。
Oncol Lett. 2018 Nov;16(5):6815-6821. doi: 10.3892/ol.2018.9423. Epub 2018 Sep 7.
9
TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.TERTp 突变与滤泡细胞来源的甲状腺癌侵袭性组织学亚型患者的无进展生存期缩短相关。
Endocrine. 2018 Sep;61(3):489-498. doi: 10.1007/s12020-018-1642-0. Epub 2018 Jun 15.
10
BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.甲状腺乳头状癌中的 BRAF 和 NRAS 突变与原发灶和相应淋巴结转移灶中 BRAF 突变的一致性。
Sci Rep. 2017 Jul 5;7(1):4666. doi: 10.1038/s41598-017-04948-3.
根据 BRAF(V600E) 突变状态制定的管理指南对甲状腺结节的手术结果。
J Clin Endocrinol Metab. 2011 Mar;96(3):658-64. doi: 10.1210/jc.2010-1082. Epub 2011 Jan 14.
4
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.促甲状腺激素受体信号对小鼠 BRAF 诱导甲状腺肿瘤起始的依赖性。
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20. doi: 10.1073/pnas.1015557108. Epub 2011 Jan 10.
5
Cancer: Small papillary thyroid cancers--is BRAF of prognostic value?癌症:微小乳头状甲状腺癌——BRAF 是否具有预后价值?
Nat Rev Endocrinol. 2011 Jan;7(1):9-10. doi: 10.1038/nrendo.2010.213.
6
The utility of BRAF testing in the management of papillary thyroid cancer.BRAF 检测在甲状腺乳头状癌管理中的应用。
Oncologist. 2010;15(12):1285-93. doi: 10.1634/theoncologist.2010-0156. Epub 2010 Dec 8.
7
Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.根据甲状腺外侵犯程度对甲状腺癌的分子、形态和预后分析。
Thyroid. 2010 Oct;20(10):1085-93. doi: 10.1089/thy.2010.0174.
8
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.BRAF V600E 突变与小于 20 毫米的甲状腺乳头状癌侵袭性的相关性:1060 例分析。
J Clin Endocrinol Metab. 2010 Sep;95(9):4197-205. doi: 10.1210/jc.2010-0337. Epub 2010 Jul 14.
9
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.根据滤泡型甲状腺癌的组织学亚型(包裹型与浸润型)进行分子基因分型,揭示了独特的 BRAF 和 RAS 突变模式。
Mod Pathol. 2010 Sep;23(9):1191-200. doi: 10.1038/modpathol.2010.112. Epub 2010 Jun 4.
10
Molecular pathology of thyroid tumors: diagnostic and prognostic relevance.甲状腺肿瘤的分子病理学:诊断及预后相关性
Int J Surg Pathol. 2010 Jun;18(3 Suppl):209S-212S. doi: 10.1177/1066896910370886.